Methods for detecting protein-protein interactions (PPIs) report evidence that two proteins associate, sit in proximity, or bind with a measurable kinetic. Protein-protein interactions methods for detection and analysis, identifying protein-protein interactions, protein-protein interaction detection methods and analysis, detecting protein-protein interactions, and protein interaction detection name the same evidence problem. They do not name a second assay. A yeast two-hybrid (Y2H) reporter, a co-immunoprecipitation (Co-IP) recovery, an affinity purification-mass spectrometry (AP-MS) list, and a proximity-labeling set are not interchangeable proofs. The valid result is a candidate association at the level the method was built for. The design does not issue a diagnostic cutoff, a personalized treatment plan, or a drug-target certificate.

Researchers who already have defined bait proteins, comparison groups, or a specific project objective can also review the MtoZ Biolabs IP-MS Protein Interactomics Analysis Service for project-specific feasibility and analysis planning.

What a PPI Detection Result Can Claim

The first decision is the sentence the assay must support. A genetic reporter says two fusion proteins reconstituted a readout in a test cell. A biochemical enrichment says a partner co-recovered with a bait from a lysate. A mass-spectrometry list names proteins that survived that enrichment. A proximity label says a protein was close enough to be marked. A biophysical trace reports binding kinetics on a sensor. Mixing those sentences is the usual source of over-read tables.

Stable complexes, such as multi-subunit machines, tolerate longer washes. Transient or weak contacts in signaling often do not. Direct contact and membership in the same complex are different claims. Co-recovery does not prove a binary interface. Disease names, crop-stress stories, and environmental catalogs describe why a bait was chosen. They do not convert a candidate list into a therapeutic or diagnostic certificate.

A PPI method reports the association evidence it was built to record, not a renamed pathway or treatment plan.

Methods Grouped by the Evidence They Record

Y2H fuses one protein to a DNA-binding domain and the other to an activation domain in yeast (Fields and Song 1989). Interaction reconstitutes transcription of a reporter. The screen is high-throughput and genetic. It is not an in-lysate biochemical assay, and it is a poor default for many transmembrane proteins. False-positive and false-negative rates require orthogonal follow-up.

Fluorescence resonance energy transfer (FRET) and bimolecular fluorescence complementation (BiFC) report spatial proximity or fragment reconstitution in living cells. They supply localization context that a bead elution lacks. Background fluorescence and the fusion itself can create signal that is not a native contact. Bimolecular luciferase complementation follows the same logic with a luminescent split enzyme.

Co-IP uses an antibody to recover an endogenous bait and associated proteins from a non-denaturing lysate. Western blot tests a prechosen partner. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) expands the searchable partner space. Antibody specificity, epitope access, and bead background set the claim. Co-IP does not, by itself, measure binding affinity or interaction strength.

A pull-down immobilizes a tagged or recombinant bait, often glutathione S-transferase (GST) or polyhistidine, and offers a lysate or purified partner. The assay tests binding under controlled chemistry. It does not reconstruct the full endogenous complex architecture.

AP-MS purifies a tagged bait expressed in a defined system and identifies co-purifying proteins by MS (Gingras et al. 2007). IP-MS and Co-IP-MS recover an antibody-captured bait, usually endogenous, then identify co-enriched proteins. Tag effects, overexpression, and antibody failure are different failure modes. Cross-linking mass spectrometry (XL-MS) covalently traps spatially close residues and can support an interface or topology claim that a simple partner list cannot. Proximity labeling, including BioID and TurboID, biotinylates neighboring proteins for streptavidin enrichment and MS (Roux et al. 2012). Proximity is not proof of a physical contact.

Surface plasmon resonance (SPR) and bio-layer interferometry (BLI) record association and dissociation on a sensor. They answer kinetic and affinity questions for a defined pair. They do not replace an open interactome search. A protein microarray can screen many spotted proteins. Activity and folding of the arrayed set remain limits. Sequence-based computational prediction is not a detection method. Stable isotope labeling by amino acids in cell culture (SILAC) or tandem mass tags (TMT) can quantify an already-enriched set. They do not create the interaction evidence.

In MtoZ Biolabs IP-MS offerings, antibody or tag enrichment is typically paired with LC-MS/MS identification of co-recovered proteins. Service configuration is not an academic rule that other laboratories must copy, and it does not include a diagnostic or GMP release intended use.

Method	Evidence recorded	Typical fit	Default limit
Y2H	Genetic reporter in yeast	Pair screening	False calls; poor membrane default
Co-IP or IP-MS	Antibody co-recovery, optional MS list	Endogenous bait, available IP antibody	Antibody and bead background
Pull-down	Immobilized recombinant bait binding	Pair or domain test	Non-native architecture
AP-MS	Tagged-bait enrichment plus MS list	Systematic tagged interactome	Tag and expression artifacts
BioID or TurboID	Proximity biotinylation plus MS	Transient or poorly soluble contacts	Proximity, not direct binding
XL-MS	Cross-linked peptides	Interface or complex topology	Chemistry and peptide complexity
SPR or BLI	Sensor kinetics	Defined-pair affinity	Not an open partner search

Figure 1. PPI methods differ by evidence: a genetic reporter, biochemical enrichment, MS identification of recovered proteins, or proximity labeling.

When the remaining decision is which mass-spectrometry enrichment route to use, researchers can refer to IP-MS vs. Co-IP-MS vs. AP-MS: Which Workflow Fits Your Study? for a more detailed strategy-selection framework.

When a Detection Method Fits the Study

A method fits when the needed claim matches the evidence type and the bait format is available. A closed pair with a working antibody can start as Co-IP plus Western blot or IP-MS. An open partner search with an endogenous bait needs an immunoprecipitation-capable antibody and controls that can rank enrichment. An open search without a usable antibody, and with tagging allowed, fits AP-MS. A hypothesis that two purified proteins can bind fits a pull-down. Transient or poorly soluble neighborhood questions fit proximity labeling. An interface question fits XL-MS after the complex can be recovered. A kinetic constant for a defined pair fits SPR or BLI.

Reassess the method when the list is still a disease-name catalog rather than a bait list, when no antibody or tag plan exists, or when the paper needs a locked diagnostic cutoff. Raman spectra, confocal colocalization, and multi-omics overlays can add context. They do not, by themselves, detect a PPI.

Researchers who need to determine whether an endogenous antibody capture or a tagged recombinant bait better matches the claim can refer to Endogenous IP-MS vs Tagged Pull-Down MS Strategies for more detailed guidance.

Figure 2. Method fit follows the claim: closed-pair validation, open partner search, defined-pair kinetics, or interface mapping.

An application name does not turn one PPI assay into proof of every other interaction claim.

How PPI Detection Results Should Be Read

A partner list is a ranked set of candidates. Sticky proteins, residual abundant contaminants, and bead binders recur across unrelated baits (Mellacheruvu et al. 2013). Empty-tag, isotype immunoglobulin, and bead-only controls belong in the design before ranking. Reciprocal recovery, a second method class, or a functional test is the usual next claim, not a larger font on the first table.

Y2H positives still need a biochemical or MS check in the relevant cell type. A Co-IP band that depends on a poorly characterized antibody is not a complex map. A BioID hit that never co-purifies under mild lysis may be a neighbor rather than a binder. An SPR Kd measured on a sensor does not prove the same pair occupies a tissue complex.

Lysis buffer, wash stringency, temperature, and protease control change which contacts survive. Harsh washes favor stable machines and lose weak signaling contacts. Matching those conditions to the intended claim matters more than listing more method names.

Frequently Asked Questions

1. Is yeast two-hybrid an in vitro detection method?

No. Y2H is a genetic reporter in yeast cells. A lysate pull-down or Co-IP is the biochemical in-vitro class.

2. Does Co-IP prove that two proteins bind directly?

No. Co-recovery shows that a partner survived enrichment with the bait. Direct contact needs a defined-pair test or an interface measurement.

3. Is BioID the same experiment as AP-MS?

No. BioID labels proteins in proximity for later streptavidin capture. AP-MS recovers proteins that remain bound to a tagged bait through purification.

4. Does a PPI detection panel become a diagnostic or drug-development certificate?

No. A research association in a defined system is not a diagnostic cutoff or a proof of target occupancy. Those uses need a locked intended use and evidence outside a discovery enrichment.

Once the bait format, intended evidence type, controls, and expected association claim are defined, the project can be evaluated as a PPI detection study. Researchers can review the MtoZ Biolabs IP-MS Protein Interactomics Analysis Service for project-specific sample evaluation, feasibility assessment, and workflow planning.